Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease - Trial NCT05901818
Access comprehensive clinical trial information for NCT05901818 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xuanwu Hospital, Beijing and is currently Recruiting. The study focuses on Parkinson's Disease. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Xuanwu Hospital, Beijing
Timeline & Enrollment
Phase 1
Jun 13, 2023
Dec 31, 2026
Primary Outcome
Assessment of changes during the medication off time in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III, in comparison with baseline values.,Incidence and severity of transplant-related adverse events.
Summary
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the
 safety and efficacy of the striatal transplantation of autologous induced neural stem
 cell-derived DA precursor cells in Parkinson's Disease patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05901818
Non-Device Trial